The Role of Early Molecular Response in the Management of Chronic Phase CML
Open Access
- 12 April 2017
- journal article
- review article
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 12 (2) , 79-84
Abstract
Purpose of Review Although tyrosine kinase inhibitors (TKIs) spectacularly improve the disease burden and the overall survival of chronic myeloid leukemia patients, early identification of a subset of poor TKI responders has been recognized as a critical goal to prevent disease progression in these patients. We herein review the past and recent evidence on the impact of early response. Recent Findings In the recent years, the achievement of an early molecular response (EMR, defined as 3-month BCR-ABL1 transcript BCR-ABL1 transcript level (halving time or velocity of ratio reduction). Summary Standardization of halving time or velocity of ratio reduction will likely help establishing more stringent recommendation and modify current clinical practices.Keywords
Funding Information
- King's College London
This publication has 39 references indexed in Scilit:
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationshipsBlood, 2013
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetBlood, 2011
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood, 2010
- Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease ProgressionJournal of Clinical Oncology, 2008
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat AnalysisJournal of Clinical Oncology, 2008
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood, 2006
- Chronic Myeloid Leukemia — Advances in Biology and New Approaches to TreatmentNew England Journal of Medicine, 2003
- Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon αLeukemia, 2002
- Characteristics of accelerated disease in chronic myelogenous leukemiaCancer, 1988